Skip to content

Early-bird registration discount for 2023 Annual Ataxia Conference ending soon. LEARN MORE!

National Ataxia Foundation

Accelerate!

Using wearable and mobile data to diagnose and monitor movement disorders

Using wearable and mobile data to diagnose and monitor movement disorders

The goal of the study is to use data from a smartphone to differentiate diseases and measure symptom severity.

ClinicalTrials.gov Link: clinicaltrials.gov/ct2/show/NCT04231487

About the Study

Eligible Ataxia Types
Spinocerebellar Ataxias

Type of Study
Research Study

Clinical Trial Phase
N/A

Age Range
Adult 18+

Study Start Date
11/01/2018

Estimated Completion Date
11/01/2023

IRB Approval #
Pro2018002015

Location(s)

Rutgers University
65 Bergen Street
Newark, NJ

Contact Information

Jean-Francois Daneault
jf.daneault@rutgers.edu
Phone: 973-972-8482

What does participation in the study entail?

Participation entails coming to the laboratory located in Newark NJ, for one session lasting about 1 hour. Some people may be asked to use the smartphone app at home, once a week, for 8 weeks.

What are the potential benefits for participants?

Participants will not benefit directly from the study. They will help us develop a tool that may become available to individuals with ataxia to improve their diagnosis and long-term management. 

What are the potential risks for participants?

The risks are no greater than doing regular activities during daily life, such as walking.

Is there financial compensation?

Yes. $40.

Is there travel reimbursement?

No.

Who is eligible?

Adults with a diagnosis of spinocerebellar ataxia and that have been on a stable dose of medication for at least 30 days are eligible. People with severe cognitive impairment that limit their understanding of simple instructions, that have a diagnosis of another neurological condition, and that have severe mobility impairments due to other conditions, such as arthritis, are not eligible.

View Other Research Opportunities

Print Friendly, PDF & Email

The goal of the study is to use data from a smartphone to differentiate diseases and measure symptom severity.

ClinicalTrials.gov Link: clinicaltrials.gov/ct2/show/NCT04231487

About the Study

Eligible Ataxia Types
Spinocerebellar Ataxias

Type of Study
Research Study

Clinical Trial Phase
N/A

Age Range
Adult 18+

Study Start Date
11/01/2018

Estimated Completion Date
11/01/2023

IRB Approval #
Pro2018002015

Location(s)

Rutgers University
65 Bergen Street
Newark, NJ

Contact Information

Jean-Francois Daneault
jf.daneault@rutgers.edu
Phone: 973-972-8482

What does participation in the study entail?

Participation entails coming to the laboratory located in Newark NJ, for one session lasting about 1 hour. Some people may be asked to use the smartphone app at home, once a week, for 8 weeks.

What are the potential benefits for participants?

Participants will not benefit directly from the study. They will help us develop a tool that may become available to individuals with ataxia to improve their diagnosis and long-term management. 

What are the potential risks for participants?

The risks are no greater than doing regular activities during daily life, such as walking.

Is there financial compensation?

Yes. $40.

Is there travel reimbursement?

No.

Who is eligible?

Adults with a diagnosis of spinocerebellar ataxia and that have been on a stable dose of medication for at least 30 days are eligible. People with severe cognitive impairment that limit their understanding of simple instructions, that have a diagnosis of another neurological condition, and that have severe mobility impairments due to other conditions, such as arthritis, are not eligible.

View Other Research Opportunities

Print Friendly, PDF & Email
Translate »

Are you ready for fun and learning at the largest Ataxia conference of the year?

2023 Annual Ataxia Conference: Partnering for Progress

Join us to connect, learn, and take action toward accelerating treatment development!